HOME CANCER GLOSSARY  CANCER PHOTOS  NEW CANCER BOOKS  LINKING  ADVERTISE

   
 

Free Financial Help for Cancer Patients
Gov't regulated program

Breast Cancer "Switch" Found

Cancer Pictures

Best Natl Cancer Ctrs

Cancer Centers
by State


Cancer Societies

Newest Treatments
by cancer type

MyCancerNews.com

Cancer Newsletters

Medical Journals

Cancer Calculator

Nat'l Cancer Inst.

MedLine Cancer

Chemotherapy

Other helpful links

Additional Help
for Cancer Patients

More Cancer Photos

Diabetes Current Topics in Diabetes

A Pill to Prevent Diabetes?


Author:

Karen Barrow

Medically Reviewed On: February 27, 2007

For the most part, people who are at high risk for type 2 diabetes have several things they can do to lower their risk of developing the disease: maintain a healthy weight, exercise and limit sweets.

But a new study has found that a drug may also be added to this equation to reduce one’s risk even more.

A team of researchers have found that a common diabetes drug may not only help those with diabetes manage their disease, but also help those at risk for type 2 diabetes avoid getting the disease in the first place.

Insulin is a hormone produced by the body to help metabolize glucose. In people with type 2 diabetes, the body does not produce enough insulin or the insulin it does produce does not work properly. As a result, the body cannot adjust adequately to changing levels of glucose. Pre-diabetes, on the other hand, is a condition that is considered to be a precursor to diabetes, when the body begins to have a lower tolerance for glucose.

In the study, researchers from Canada looked at over 5,000 adults with some symptoms of pre-diabetes. Half of the participants were given a standard dose of rosiglitazone (Avandia), a drug commonly used to treat people with full-blown type 2 diabetes.

Over the course of three years, the participants were monitored for the development of diabetes. By the end of the study, those taking the drug seemed to have reduced their chance of developing type 2 diabetes by almost 60 percent.

“The results of this study suggest that the addition of rosiglitazone to basic lifestyle recommendations substantially reduces the risk of developing diabetes by about two-thirds,” writes Dr. Nicholas Wareham, lead author of the study, published in the Lancet.

However, the authors do not suggest that those at risk for developing diabetes begin to take this drug, “despite the impressive risk reduction for progression to diabetes.” Barriers to offering this drug to those at high risk include the lack of data on long-term benefits and side-effects, along with the high cost of therapy.

Additionally, when taken long term, the drug carries a risk of heart failure. “The greater benefits in higher risk individuals would have to be balanced against the likely risk of heat failure,” writes Wareham.

 

Alternative Therapies

Melanoma Skin Cancer

Complementary and Alternative Cancer
Care Guidelines

Cancer Treatment Research Library

Dangerous Doctors
...is yours safe?

Cancer Archives

 

 

MEMBERSHIPS:     

About us
Privacy policy
Conditions of use

 


Nat'l Cervical
Cancer Coalition

logo nbtf
National Brain
Tumor
Foundation


Nat'l Ovarian
Cancer Coalition


Breast Cancer
Research

MCN
My
Cancer News

 

Special
Thanks
 TECH SUPPORT

Codebrain
Codebelly


NOTICE:  No information on this CANCER research site is provided, intended or implied to substitute for trained, professional medical advice, CANCER diagnosis or CANCER treatmentAs a condition of use of this cancer website, all visitors agree to seek trained medical advice before using any cancer treatment or cancer information found on this website and agree discuss these with their physicians prior to use and to hold RobertsReview and all entities affiliated with, contributing to, and/or operating this cancer research website harmless in regard to all information provided herein and/or from any decisions that may flow from use of this information.  RobertsReview in no way recommends, endorses or verifies the accuracy or claims of any of the cancer information provided herein by "third parties" regardless of their affiliation.

©1997-2006 RobertsReview, Wickford, RI USA. No information contained on this website may be reproduced in any form in any media.  Single copies may be reprinted for non-commercial use.